Clinical Trial

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2024 (before its estimated February 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is to examine the anticancer activity of the combination therapy with all-trans retinoic acid and nivolumab in patients with chemotherapy-refractory advanced or metastatic pancreatic adenocarcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-07-28; most recent amendment 2024-08-19.
Status change: Recruiting → Active, Not Recruiting 2024-08-19
Status change: Active, Not Recruiting → Recruiting 2023-02-16
Status change: Completed → Active, Not Recruiting 2022-09-27
Trial Details
NCT Number NCT05482451
Lead Sponsor China Medical University Hospital
Conditions Effect of Drug
Enrollment 10 participants
Start Date 2021-03-01
Primary Completion 2025-02-28 (estimated)
Study Completion 2025-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-08-21